|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis Report - Diabetes/Obesity Q4 2010
Medpredict, Nov 2010, Pages: 132
MedPredict interviewed N. American and European thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Drug classes discussed include biguanides (metformin), DPP4 inhibitors, GLP-1 agonists, PPAR, secretagogues, SGLT2, GPR-119, insulins and (briefly) amphetamines.
Some of the questions addressed by this panel include:
- What are the advantages and disadvantages of GLP-1 agonists vs. DPP4 inhibitors?
- What will be the impact of the FDA’s complete response letter to Lilly/Amylin requesting additional Bydureon data uptake of Novo Nordisk’s Victoza?
- What are Victoza’s advantages vs. Lilly/Amylin’s Byetta?
- Is the increased pancreatitis seen with GLP-1’s due to mechanism of action, or related to the disease condition?
- What will be one of the keys to physician acceptance of SGLT2 inhibitors?
- How do panelists distinguish between Merck’s Januvia and BMS/AZ’s Onglyza?
- How will Kombiglyze XR (a once-daily form of saxagliptin just approved by FDA) or Boehringer Ingelheim’s Ondero (linagliptin, expected filing 4Q 2010) impact prescribing in the DPP4 class?
- What is the outlook for MannKind’s inhaled insulin product, Afrezza? Will their Technosphere delivery system overcome the negative impact on lung function that caused Pfizer’s Exubera to be discontinued?
Full transcripts of six qualitative interviews with endocrinologists are included with this report.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
